Clovis Oncology, Inc. is a biopharmaceutical firm dedicated to the acquisition, development, and commercialization of oncology therapeutics across the United States, Europe, and globally. Within the United States, their flagship product is Rubraca (rucaparib), an orally administered small molecule that inhibits poly ADP-ribose polymerase (PARP), indicated for recurring epithelial ovarian, fallopian tube, or primary peritoneal malignancies, as well as for metastatic castration-resistant prostate cancer. European markets see Rubraca approved for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company's pipeline further includes lucitanib, an investigational angiogenesis inhibitor that targets vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived growth factor receptors (PDGFRa/ß), and fibroblast growth factor receptors (FGFR 1-3), and FAP-2286, an experimental peptide-targeted radionuclide therapy and diagnostic agent specifically designed to target fibroblast activation protein. Rubraca's distribution model relies on a select network of specialty distributors and pharmacies, which in turn supply the medication to patients and medical professionals. The company maintains licensing agreements with prominent entities such as Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical partnership with Bristol Myers Squibb Company, and a strategic alliance with Foundation Medicine, Inc. Established in 2009, Clovis Oncology is headquartered in Boulder, Colorado. However, on December 11, 2022, Clovis Oncology, Inc., along with its affiliated entities, initiated voluntary Chapter 11 reorganization proceedings in the U.S. Bankruptcy Court for the District of Delaware.